Results 171 to 180 of about 316,033 (212)

Update on Chronic Hepatitis C

Clinical Gastroenterology and Hepatology, 2005
The burden of chronic hepatitis C infection remains significant in the United States and worldwide. Increased knowledge regarding the natural history of acute and chronic infection and the key factors responsible for disease progression, risk for cirrhosis, and risk for hepatocellular carcinoma are critical in guiding secondary and tertiary prevention ...
Winnie, Wong, Norah, Terrault
openaire   +2 more sources

Pathology of Chronic Hepatitis B and Chronic Hepatitis C

Clinics in Liver Disease, 2010
Histologic evaluation of the liver is a major component in the medical management and treatment algorithm of patients with chronic hepatitis B (HBV) and chronic hepatitis C (HCV). Liver biopsy in these patients remains the gold standard, and decisions on treatment are often predicated on the degree of damage and stage of fibrosis. This article outlines
openaire   +2 more sources

THERAPY FOR CHRONIC HEPATITIS C

Gastroenterology Clinics of North America, 1994
Hepatitis C is the silent epidemic of the 1970s and 1980s. Interferon alfa is currently the only effective treatment. Enthusiasm for interferon therapy must be tempered because advanced disease usually requires years or even decades to develop and does not occur in all patients.
G L, Davis, J Y, Lau, H L, Lim
openaire   +2 more sources

Therapy for chronic hepatitis C

Journal of Physiology-Paris, 2001
in Hungary, over the past 5 years more than 900 patients with chronic hepatitis C have been examined for treatment with interferon at 16 major hepatology centres, using unified diagnostic and therapeutical criteria. Authors give an account of their experiences on the clinical features of patients with chronic hepatitis C and report the results of the ...
Pár, Alajos, Telegdy, László, Dalmi, Lajos, Müller, Éva   +3 more
openaire   +3 more sources

Treatment of chronic hepatitis C

Journal of Hepatology, 1991
alpha-Interferon given subcutaneously at doses between 1-3 million units leads to responses in about 50% of patients suffering from chronic hepatitis C. A 24-week treatment is frequently (approx. 50%) followed by relapses reducing the percentage of lasting responders to approx. 20%.
openaire   +2 more sources

Treatment for chronic hepatitis C

Current Gastroenterology Reports, 2003
Approximately four million Americans have been exposed to the hepatitis C virus (HCV) and are anti-HCV positive; almost three million are chronically infected and HCV RNA positive. Treatment for chronic hepatitis C has improved rapidly over the past 12 years from interferon monotherapy, with a sustained virologic response (SVR) rate of about 10% in the
openaire   +2 more sources

Hepatic sarcoidosis associated with chronic hepatitis C

Journal of Gastroenterology, 2002
A 57-year-old woman with sarcoidosis was referred because of the appearance of multiple small low-attenuation areas in the liver on computed tomography (CT). A liver biopsy specimen showed chronic active hepatitis accompanied by sarcoid granulomas. The patient received prednisolone and, later, interferon-alpha.
Shinwa, Yamada, Shinichiro, Mine, Takeshi, Fujisaki, Norihiro, Ohnari, Sumiya, Eto, Yoshiya, Tanaka   +5 more
openaire   +2 more sources

Economics of chronic hepatitis B and hepatitis C

Journal of Hepatology, 2007
Although not all patients develop progressive liver disease, chronic hepatitis B and chronic hepatitis C infections cause substantial morbidity and mortality worldwide. To address this need, many new antiviral treatments have become available over the past 10 years.
Arathi, Rajendra, John B, Wong
openaire   +2 more sources

Antifibrotics for Chronic Hepatitis C

Clinics in Liver Disease, 2009
Development and testing of antifibrotic agents for the treatment of chronic hepatitis C have generally been targeted toward hepatic stellate cells, transforming growth factor-beta, the inflammatory response, or extracellular matrix accumulation. Although several agents such as interferon-gamma, long-term pegylated interferon, and caspase inhibitors ...
openaire   +2 more sources

Chronic hepatitis C

Disease-a-Month, 1994
Formerly the diagnosis of acute and chronic non-A, non-B hepatitis was made by the exclusion of other causes. However, in 1989 cloning of an antigenic component of the hepatitis C virus (HCV) was reported. This led to first- and second-generation tests for antibody to HCV (anti-HCV) in serum.
  +5 more sources